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Unilateral forms of primary aldosteronism (PA) are usually surgically treated to remove the 
source of aldosterone excess. After adrenalectomy, aldosteronism persists in some patients 
indicating abnormal aldosterone production from the unresected gland. Our objective was to 
investigate histopathology, genotype and postsurgical outcomes in a 3-year prospective 
cohort of surgically treated patients for PA (from 2016 to 2018). The cohort comprised 60 
consecutively operated patients categorized with classical or nonclassical histopathologic 
findings of unilateral PA. In the classical group were 45 solitary aldosterone-producing 
adenomas or dominant aldosterone-producing nodules; in the nonclassical group, 15 cases of 
multiple aldosterone-producing micronodules or nodules (12 cases), or aldosterone-
producing diffuse hyperplasia (3 cases). The classical group displayed higher baseline plasma 
aldosterone concentrations (262 versus 155 pg/mL, P=0.008) and an increased aldosterone-
to-renin ratio (81 versus 42, P=0.002). A high proportion of the classical group achieved 
complete biochemical success (97.6% versus 66.7% in the nonclassical group, P=0.002). The 
nonclassical versus classical group displayed an increased ratio of absolute aldosterone 
concentration in the contralateral adrenal vein to peripheral vein at adrenal venous sampling 
(3.8 versus 2.0, P=0.004). Variants in aldosterone-driver genes were identified in 85% of 41 
APAs and were excluded in the remaining 15% by CYP11B2 guided next generation 
sequencing. There were no differences in clinical or biochemical outcomes in patients with a 
solitary APA categorized by KCNJ5 mutation status. In conclusion, adrenals with a nonclassical 
histopathology of unilateral PA are associated with a higher incidence of disease persistence 
and increased aldosterone production from the unresected adrenal. 
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Unilateral primary aldosteronism (PA) is the most common surgically correctable form of 
hypertension1,2 usually caused by aldosterone overproduction from an adrenocortical 
aldosterone-producing adenoma (APA). Surgical resection of the diseased gland should 
remove the source of aldosterone excess but postsurgical aldosteronism (partial and absent 
biochemical success) persists in 6% of patients when unilateral forms are identified by adrenal 
venous sampling (AVS).3 When subtype differentiation is performed by AVS, postsurgical 
persistence is likely accounted for by presurgical highly asymmetrical forms of bilateral PA. 
 
CYP11B2 immunohistochemistry of the resected glands determines the expression of 
aldosterone synthase and the probable source of aldosterone production.4,5 We and others 
have previously reported the utility of routine adrenal CYP11B2 immunostaining in the 
histopathologic diagnosis of surgically treated patients with PA.6-10 Recently, an international 
group of pathologists and adrenal experts published the HISTALDO (histopathology of primary 
aldosteronism) consensus to standardize the previously discordant nomenclature for 
histopathologic features of adrenals from patients with PA.10  
 
Somatic variants in genes involved in the control of intracellular ion homeostasis have been 
identified that drive the overproduction of aldosterone in APAs.11,12 CYP11B2 
immunohistochemistry has been used as a guide to identify regions in formalin-fixed paraffin 
embedded (FFPE) tissue sections for genotyping by targeted next generation sequencing 
(NGS) panels focusing on selected genes associated with PA.13-15 This approach of CYP11B2-
guided amplicon NGS helped identify mutations in aldosterone-driver genes in 88-96% of 
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APAs13-15 and a CYP11B2 guided whole-exome sequencing method also identified somatic 
variants in additional genes16,17. 
 
We investigated the molecular and clinical pathology of a 3-year prospective series of 
surgically treated patients with PA operated from 2016 to 2018 diagnosed at a single tertiary 
referral center. Our aims were to determine i) the prevalence and clinical presentation of 
different histopathologic forms of PA; ii) the association of defined histopathologic 
phenotypes with abnormal aldosterone production from the contralateral adrenal gland at 
baseline and with postsurgical outcomes; (iii) the prevalence of variants in aldosterone-driver 
genes in APAs and potential association with postsurgical outcomes. 
 
Materials and Methods 
The expanded methods are available in the Data Supplement. The authors declare that all 
supporting data are available within the article and the Data Supplement. 
 
Patient cohort 
The study included all consecutively operated patients for PA who gave written informed 
consent for use of clinical data and biomaterial in accordance with the local ethics 
committee over a 3-year period (2016 to 2018) at the Klinikum der Ludwig-Maximilians-
Universität München, Munich, Germany. Accordingly, 60 patients were included from a total 
of 66 patients treated by unilateral laparoscopic adrenalectomy for PA over the same period 
at the same centre. 
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The diagnosis of PA and subtype differentiation by adrenal venous sampling (AVS) was based 
on the Endocrine Society Guideline18 and by local criteria19. Follow-up data were available for 
54 of 60 patients at 6-12 months after surgery. Clinical and biochemical outcomes were 
assessed according to the PASO criteria.3 There were 3 patients who bypassed AVS for subtype 
differentiation. Two of these patients met the criteria predictive of cure20,21 and were 
classified as complete biochemical success after surgery3. The third patient refused AVS but 
was favourable for surgery despite counselling of 20% probability of failure20 and the 
postsurgical outcome was classified as absent biochemical success.  
 
Histopathology 
Haematoxylin and eosin (H&E) staining and CYP11B2 immunostaining4 (clone 41-17B, a kind 
gift from Celso E. Gomez-Sanchez, University of Mississippi Medical Center, Jackson, MS, USA) 
was performed on 3 µm thick FFPE adrenal tissue sections as described previously.7 Tissue 
sections of all blocks from each resected adrenal were evaluated by H&E and CYP11B2 
immunostaining and adrenal specimens were categorized as classical or nonclassical 
histopathological findings of unilateral PA according to the HISTALDO consensus.10 The 
classical group comprised adrenals with solitary APAs (aldosterone-producing adenomas) and 
dominant APNs (aldosterone-producing nodules). The nonclassical group comprised adrenals 
without an APA or dominant APN, but with multiple aldosterone-producing nodules or 
aldosterone-producing micronodules (previously referred to as aldosterone-producing cell 




All adrenals with a solitary APA or dominant APN were used for CYP11B2 guided targeted 
Sanger sequencing using FFPE adrenal samples.22 The genotype of mutation negative samples 
was validated by CYP11B2 guided targeted amplicon next generation sequencing.13,17 For 2 
solitary APAs (diameter 28 mm and 10 mm), exome sequencing was performed on fresh 
frozen tissue (Eurofins Genomics, Ebersberg, Germany). For all mutation-positive samples, 
leukocyte DNA or a CYP11B2-negative region of adrenal from the same patient was sequenced 
for the presence of the same mutation.   
 
Statistical Analysis 
Statistical analyses were performed using IBM SPSS Statistics 26 or GraphPad Prism version 
8.4.2. Clinical and biochemical parameters are shown as medians and interquartile ranges, 
means ± SD or absolute numbers and percentages. Non-normally distributed data were 
analysed using a Mann-Whitney U test or Kruskal-Wallis test for two or more groups, 
respectively. Normally distributed variables were analysed using a t-test for 2 groups or 1-
way-ANOVA with Tukey’s multiple comparisons test for >2 groups. For categorical variables, a 
Chi-squared test or Yates's chi-squared test was used. Differences were considered significant 
with a P value <0.05. 
 
Results 
Patient cohort and Histopathology 
The cohort comprised 60 patients with a mean age of 51 ± 13 years and a median known 
duration of hypertension of 103 [39-171] months. The patients were categorized into 2 groups 
according to classical versus nonclassical histopathologic findings of unilateral PA according to 
the HISTALDO consensus.9 There was no difference in age, sex distribution or duration of 
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hypertension between the classical and nonclassical groups. Patients with a solitary APA or 
dominant APN (classical histopathology group) displayed higher baseline plasma aldosterone 
concentrations (262 pg/mL [164-356] versus 155 pg/mL [129-180], P=0.008) and an increased 
aldosterone-to-renin ratio (81 [45-116] versus 42 [28-50], P=0.002) compared with the 
nonclassical group (Table 1).  
 
The 60 adrenal samples comprised 45 with the classical histopathology (solitary APA or 
dominant APN) and 15 with nonclassical findings comprising multiple aldosterone-producing 
nodules or micronodules (12 cases) or aldosterone-producing diffuse hyperplasia (3 cases) 
(Figure 1A). More than half (58%) of the 45 adrenals with a solitary APA or dominant APN 
displayed aldosterone-producing lesions in the adjacent cortex (multiple aldosterone-
producing micronodules or aldosterone-producing diffuse hyperplasia in 23 and 3 cases, 
respectively) (Figure 1B). The categorization of the resected adrenals according to 
histopathologic findings is shown in Figure 2. 
 
Histopathology and postsurgical outcomes 
Follow-up parameters were available for 54 of 60 patients for assessment of clinical and 
biochemical outcomes according to the international PASO criteria.3 Postsurgical complete 
clinical success with normalization of blood pressure was observed in 18.5% of patients, and 
a further 57.4% displayed partial clinical success with significant clinical improvements (Figure 
3). Notwithstanding the absence of significant differences in clinical outcomes between the 
classical versus nonclassical histopathology groups (P=0.224), the proportion of patients with 
absent clinical success was around 2-fold higher in the nonclassical compared with the 
classical group (41.7% versus 19%). 
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In the total cohort, postsurgical complete biochemical success was observed in 90.7% of 
patients. This proportion increased to 97.6% in patients with the classical histopathology of a 
solitary APA or dominant APN compared with 66.7% in the nonclassical group (P=0.004). Of 
note, the presence of aldosterone-producing lesions in the adjacent cortex of 26 of 45 (58%) 
of the classical cases did not have a negative effect on the biochemical outcomes of these 
patients. 
 
Histopathology and contralateral suppression  
The differences in biochemical outcomes suggested baseline abnormal aldosterone 
production from the contralateral gland in a significant proportion of patients with the 
nonclassical histopathology group. Using unstimulated AVS results, we evaluated 
contralateral suppression of aldosterone production from the ratio of the absolute 
aldosterone concentration in the contralateral adrenal vein to the peripheral vein (ACL/AP). 
Overall, contralateral suppression was observed in 7% (4 of 54) of cases, with all 4 cases 
occurring in patients with the classical histopathology. Further, the ratio of absolute 
aldosterone concentration in the contralateral adrenal vein to the peripheral vein was 
increased in the nonclassical compared with the classical histopathology group (3.8 [1.7-6.5] 
versus 2.0 [1.1-3.1], P=0.004) (Figure 3). Restricting the analysis of contralateral suppression 
(ACL/AP) to the classical histopathology group alone with categorization of adrenal samples 
according to the absence or presence of aldosterone-producing lesions in the adjacent cortex 
did not detect a between-group difference (1.6 [1.1-2.6] versus 2.3 [1.2-3.9], P=0.338).  
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Contralateral suppression indices using cortisol-corrected aldosterone concentrations did not 
reveal differences between the classical and nonclassical groups. In addition, the lateralization 
index did not significantly differ between the 2 histopathologic groups (Table S1). 
 
Prevalence of variants in aldosterone-driver genes  
All solitary APAs from patients who gave consent for genetic analysis (41 of 45 adrenals) were 
analyzed for the presence of variants in aldosterone-driver genes. A summary of the 
sequencing approach, the cDNA and corresponding protein sequence variant is shown in 
Table 2. The overall prevalence of variants in aldosterone-driver genes was 85% (35 of 41 
samples) with mutations in the KCNJ5 gene predominating (56%, 23 of 41 samples). The KCNJ5 
mutations included a novel p.L168_L169delinsKR variant, that we found in 2 different APAs, 
absent from paired leukocyte DNA (Table 2). The prevalence of mutations in the different 
aldosterone-driver genes is shown in Figure S1. Of the 41 sequenced APAs, 5 (12%) carried a 
mutation in ATP1A1, 2 (5%) in ATP2B3 and 4 (10%) in CACNA1D. Variants in CTNNB1 in this 
series were not identified and 6 APAs were mutation-negative (15% of 41 APAs), an 
observation determined by CYP11B2 guided amplicon NGS. A variant in a highly conserved 
region of the chloride voltage-gated channel 2 encoded by CLCN2 was also identified by exome 
sequencing (NM_004366.6, c.731G>A, p.C244Y), but did not appear to have a functional effect 
(Figure S2). 
 
KCNJ5 mutations and postsurgical outcomes 
Patients with classical histopathologic findings of a solitary APA or dominant APN were 
stratified into those with and without KCNJ5 variants. Of these, there were 38 patients with 
available outcome data, comprising 21 APAs with and 17 without a KCNJ5 mutation. There 
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were no differences in clinical or biochemical outcomes according to the presence or absence 
of a KCNJ5 mutation (Figure S1). 
 
Discussion 
The increased use of AVS and intensified screening for PA has increased the detection of 
milder forms23 and amplified the detection of diverse histopathologic forms of lateralized 
PA.7,24,25 Using nomenclature defined by the HISTALDO consensus9 with morphologic 
evaluation and multiple block CYP11B2 immunohistochemistry4,5, we demonstrate a solitary 
APA or a dominant aldosterone-producing nodule in ¾ of the cohort (classical histopathologic 
findings of unilateral PA). This prevalence corresponds to reports in 2 retrospective reviews of 
206 and 95 surgically treated patients for unilateral PA diagnosed by AVS that identified 
solitary adenomas in 74% and 69% of cases.26,27  
 
In contrast, aldosterone overproduction was attributed to multiple aldosterone-producing 
nodules, micronodules or diffuse hyperplasia in the remaining ¼ cases (nonclassical 
histopathologic findings of unilateral PA). Thus, adrenals without a solitary APA or a dominant 
APN were not uncommon histopathologic findings in this series of surgical adrenal specimens. 
The nonclassical histopathologic forms displayed a milder clinical phenotype with significantly 
lower plasma aldosterone concentrations and aldosterone-to-renin ratios at baseline 
compared with the classical phenotype. Specifically, the nonclassical group comprised 20% 
multiple aldosterone-producing micronodules (formerly referred to as aldosterone-producing 
cell clusters28) (or multiple aldosterone-producing nodules), or in 5% of cases, aldosterone-
producing diffuse hyperplasia.9  
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Patients with nonclassical histopathologic findings of unilateral PA were often characterized 
by aldosterone-producing micronodules, which are prevalent in some forms of bilateral PA.29 
We demonstrate that a third of patients (4 of 12) in the nonclassical group with multiple 
aldosterone-producing micronodules (or nodules) or aldosterone-producing diffuse 
hyperplasia are not biochemically cured after adrenalectomy, in contrast to 1 of 42 in the 
classical group. These findings are consistent with observations of a multicenter study that 
reported an increased incidence of adrenals with adrenocortical hyperplasia in the absence of 
a solitary APA (nonclassical form) from surgically treated patients with PA who were not 
biochemically cured after adrenalectomy with age- and sex- matched patients who were 
biochemically cured (partial + absent versus complete biochemical success).7 These data are 
in contrast to previous studies that reported no link between adrenal pathology and 
outcomes.26,27 However, neither report evaluated CYP11B2 immunohistochemistry for 
functional histopathologic assessment and outcomes were assessed just after 
adrenalectomy,26,27 in contrast to 6-12 months post-adrenalectomy as in the present study.3 
 
The presence of aldosterone-producing multiple nodules, micronodules or diffuse hyperplasia 
in the ipsilateral gland suggests their possible presence in the contralateral gland. An APA 
produces and secretes high amounts of aldosterone that suppresses the renin-angiotensin 
system and hence aldosterone production from the contralateral (non-dominant) gland, 
which is usually calculated using cortisol-corrected aldosterone concentrations in the 
contralateral adrenal vein compared with the peripheral vein.30 However, absolute 
aldosterone concentrations have also been used to evaluate the association of contralateral 
suppression with postsurgical outcomes.31,32 We were interested in quantifying aldosterone 
production from the contralateral gland. Higher absolute aldosterone concentrations in the 
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contralateral vein compared with the peripheral vein (ACL/AP ratio) would provide good 
evidence for inappropriate aldosterone secretion without requiring cortisol-correction for 
adrenal venous blood dilution during the AVS procedure because in the case of blood dilution, 
the real adrenal vein aldosterone concentrations would be even higher but not lower. Also, 
there would be no reason to correct for dilution of aldosterone in peripheral blood which 
could potentially confound the evaluation in some way. We observed an increased ACL/AP ratio 
in patients with the nonclassical histopathology, which suggests elevated aldosterone 
production from the contralateral gland at baseline compared with patients with the classical 
histopathology of a solitary APA or dominant APN. Of note, the presence of aldosterone-
producing multiple nodules, micronodules or diffuse hyperplasia in the ipsilateral adrenal in 
the presence of a solitary APA or dominant APN did not adversely influence postsurgical 
biochemical outcomes.  
 
The finding of higher aldosterone concentrations in the contralateral adrenal vein compared 
with peripheral blood in the nonclassical histopathology group suggests presurgical 
asymmetrical bilateral disease in these patients. The AVS procedure in this study was 
performed under basal conditions. However, comparison of AVS under basal conditions with 
cosyntropin (synthetic adrenocorticotropic hormone)-stimulated AVS have shown that an 
initial diagnosis of unilateral PA can switch to a diagnosis of bilateral disease with a 
cosyntropin-stimulated procedure.31 A low incidence of discordance between the 2 
approaches has been reported33 potentially explained by the strictness of the AVS criteria.34 
Wannachalee et al.35 reported different patterns of response to cosyntropin stimulation 
during AVS, an observation which may be related to baseline aldosterone concentrations and 
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aldosterone-driver mutations, but histopathological phenotype could also be a contributing 
factor. 
 
Several studies have reported variants in aldosterone-driver genes which potentially account 
for over 90% of the aldosterone overproduction from APAs.13-17 We used a similar approach 
to these studies and validated mutation-negative status of APAs by CYP11B2 guided NGS and 
found an 85% prevalence of variants in aldosterone-driver genes. Consistent with other 
reports, we did not find mutations in CTNNB1.14,15 CACNA1H variants were also absent16. 
Sequencing paired blood samples demonstrated the absence of all variants from germline 
DNA except for the rare CLCN2 variant which is likely a non-pathogenic variant because we 
found no functional effect in vitro. Despite the high prevalence of variants in aldosterone-
driver genes in this and other studies, their functional effect in the majority of cases is 
unknown and it is likely that in some cases the variants ascribed as aldosterone-driver 
mutations are non-pathogenic variants as demonstrated previously for p.CACNA1D-M1354I.36 
 
We did not find an association of APAs with KCNJ5 mutations with postsurgical outcomes. We 
excluded from the analysis patients with nonclassical histopathologic findings of unilateral PA 
to avoid negative bias of the group without a KCNJ5 mutation which likely confounded the 
findings of previous studies. 37,38 
      
Strengths and Limitations 
The strengths of this study include the analysis of a prospective cohort of surgically treated 
patients for PA with evaluation of histopathology by H&E staining and CYP11B2 
immunostaining according to the international HISTALDO consensus. In addition, all FFPE 
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blocks for each adrenal specimen were examined to assess sections from all fragments of the 
removed gland. Postsurgical outcomes were assessed by the PASO criteria and adrenal venous 
sampling results allowed the evaluation of aldosterone production from the unresected 
glands. A limitation is the heterogeneous approach used for genotype determination, but the 
mutation negative status of all samples was determined by CYP11B2 guided amplicon NGS.  
 
In conclusion, nonclassical histopathologic findings of unilateral forms of PA are associated 
with higher baseline aldosterone production from the unresected adrenal gland and a higher 
incidence of post-surgical persistent aldosteronism.  
 
Perspectives 
The application of recently established consensus criteria to assess histopathology and 
postsurgical outcomes provides relevant information for patient care. It links functional in vivo 
data of adrenal mineralocorticoid secretion with the newly defined histopathology 
phenotypes. This enables refined patient selection for surgical management and a better 
understanding of the pathophysiology of PA. 
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Novelty and Significance 
What is new? 
• The histopathology of adrenals from a 3-year prospective series of surgically treated 
patients for PA were evaluated according to the international HISTALDO consensus  
• A notable proportion displayed nonclassical histopathologic findings of unilateral PA 
with aldosterone-producing nodules or micronodules (20%) or aldosterone-producing 
diffuse hyperplasia (5%)  
• More than half the adrenals with a solitary APA displayed aldosterone-producing 
lesions (nodules, micronodules or diffuse hyperplasia) in the adjacent cortex which did 
not affect postsurgical biochemical outcomes 
• Nonclassical histopathology was associated with higher aldosterone production from 
the contralateral adrenal at AVS and a decreased incidence of postsurgical biochemical 
remission  
What Is relevant? 
• Adrenals without a solitary APA are not infrequent histopathologic findings from 
surgically treated patients for PA 
• Patients with classical histopathologic lesions stratified by presence or absence of a 
KCNJ5 mutation displayed similar postsurgical outcomes  
Summary 
Nonclassical histopathologic findings from surgically treated patients for PA are associated 
with higher baseline aldosterone production from the unresected adrenal and an increased 





Figure 1. Histopathologic evaluation of adrenals according to HISTALDO consensus 
Histopathology of surgically removed adrenals evaluated by H&E and CYP11B2 
immunohistochemistry from a 3-year prospective series of surgically treated patients for PA. 
Histopathologic features were classified according to the HISTALDO consensus9 and adrenals 
were categorized into classical and nonclassical forms of unilateral PA based on the source of 
aldosterone overproduction originating mainly from a solitary APA or a dominant APN versus 
alternative aldosterone-producing lesions (multiple aldosterone-producing nodules or 
micronodules, or aldosterone-producing diffuse hyperplasia) (A). Adrenals with classical 
histopathologic findings displayed aldosterone-producing lesions in the adjacent adrenal 
cortex in more than half of cases (B, 26 of 45 cases). Adrenals in the nonclassical group 
displayed multiple aldosterone-producing nodules or micronodules or aldosterone-producing 
diffuse hyperplasia (B). APA, aldosterone-producing adenoma; APM, aldosterone-producing 
micronodule; APN, aldosterone-producing nodule; APDH, aldosterone-producing diffuse 
hyperplasia; CYP11B2 IHC, CYP11B2 (aldosterone synthase) immunohistochemistry; H&E, 
hematoxylin and eosin; HISTALDO, histopathology of primary aldosteronism consensus; 




Figure 2. Histopathologic categorization of adrenal sample specimens 
Panels A and B show examples of classical histopathologic findings of unilateral forms of PA, 
panel C shows examples of nonclassical findings. The figure shows an APA without 
aldosterone-producing lesions in the adjacent cortex (A, sample 1); an APA with multiple 
aldosterone-producing micronodules in the adjacent cortex (B, upper panel, sample 2), and 
below, an APA with aldosterone-producing diffuse hyperplasia in the adjacent cortex in block 
A, which was clearly visualized in the fragment shown in block B (B, lower panel, sample 3). 
Examples of adrenals in the nonclassical group are also shown with multiple aldosterone-
producing micronodules (C, upper panel, sample 4), and below, aldosterone-producing 
diffuse hyperplasia (C, lower panel, sample 5). H&E, haematoxylin and eosin, CYP11B2 
(aldosterone synthase) immunohistochemistry. Scale bar represents 2 mm for the overview 








Figure 3. Postsurgical outcomes and baseline contralateral suppression stratified by 
histopathology     
Postsurgical outcomes were assessed as complete, partial and absent clinical and biochemical 
success and categorized as classical versus nonclassical histopathologic findings (A). Numbers 
of patients are indicated in parenthesis; outcome data was missing for 6 patients. A chi-
squared test was used for statistical analysis. Contralateral suppression was compared 
between patients with classical versus nonclassical histopathologic findings from the ratio of 
the absolute aldosterone concentration in the contralateral adrenal vein to the peripheral vein 
(ACL/AP) (B). Adrenal venous sampling results from the contralateral gland were available for 
40 patients in the classical group and 14 patients in the nonclassical group. The box plot 
represents the median with 25th to 75th percentiles. Group differences were analysed with a 
Mann-Whitney U test (P<0.005). ACL, aldosterone concentration in the contralateral vein; AP, 












Age at surgery (y)  60 51 ± 13 50 ± 13 52 ± 13 0.565 
Sex (ref. female) 60 31 (51.7) 25 (55.6) 6 (40.0) 0.296 
BMI (kg/m2) 60 27.6 ± 5.2 27.5 ± 5.2 28.0 ± 5.3 0.754 
Systolic BP (mmHg) 60 150 ± 17 150 ± 18 149 ± 14 0.810 
Diastolic BP (mmHg) 60 94 ± 12 94 ± 12 93 ± 12 0.715 
Anti-HTN meds (DDD) 60 2.0 [1.0-3.0] 2.0 [1.0-3.0] 1.3 [0.5-2.0] 0.083 
Duration HTN (mo) 60 103 [39-171] 108 [48-180] 78 [24-144] 0.614 
PAC (pg/mL) 60 210 [154-350] 262 [164-356] 155 [129-180] 0.008 
DRC (mU/L) 60 3.1 [2.0-5.6] 2.0 [2.0-5.0] 4.3 [2.0-6.4] 0.101 
ARR 60 68 [41-106] 81 [45-116] 42 [28-50] 0.002 
Serum K+ (mmol/L) 60 3.4 ± 0.5 3.4 ± 0.5 3.6 ± 0.5 0.102 
Largest nodule (mm) 60 12 [7-17] 14 [9-18]  5 [0-7] <0.001 
Clinical Outcome (n=54) 0.224 
Complete success 10 10 (18.5) 9 (21.4) 1 (8.3)  
Partial success 31 31 (57.4) 25 (59.6) 6 (50.0)  
Absent success 13 13 (24.1) 8 (19.0) 5 (41.7)  
Biochemical Outcome (n=54)  0.002 
Complete success 49 49 (90.7) 41 (97.6) 8 (66.7)  
Partial success 2 2 (3.7) 1 (2.4) 1 (8.3)  
Absent success 3 3 (5.6) 0 3 (25.0)  
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Table 1. Clinical characteristics of patients stratified by histopathologic findings.  
Quantitative normally distributed variables are shown as means ±SD and nonnormally 
distributed variables are reported as medians [IQR]. Categorical variables are shown as 
absolute numbers and percentages in parenthesis. P values were calculated using the Chi-
squared or Yates's chi-squared test for categorical variables or with a t-test or Mann Whitney 
U test for quantitative variables as appropriate. P<0.05 was considered significant. The 
defined daily dose (DDD) is the assumed average maintenance dose per day for a drug used 
for its main indication in adults according to the ATC/DDD Index 2019 
(https://www.whocc.no/atc_ddd_index/). Serum K+ refers to the lowest measured serum 
potassium concentration. Largest nodule indicates the largest nodule diameter measured at 
pathology. Clinical and biochemical outcomes were assessed at 6-12 months after surgery. 
ARR, aldosterone-to-renin ratio; BMI, body mass index; BP, blood pressure; CL, contralateral 
(*n=39); DDD, defined daily dose; DRC, direct renin concentration; HTN, hypertension; K+, 
potassium ions; meds, medications; PAC, plasma aldosterone concentration; ref., reference 
 
 25 
Gene cDNA change Amino acid change Sequencing approach No.  samples 
KCNJ5 c.451G>A p.G151R CYP11B2-guided Sanger seq 6 
 c.451G>C p.G151R CYP11B2-guided Sanger seq 4 
 c.503T>G  p.L168R CYP11B2-guided Sanger seq 11 
 *c.502_506delinsAAGAG p.L168_L169delinsKR 
 
CYP11B2-guided amplicon NGS 
Whole exome seq (FF) 
2 
ATP1A1 c.311T>G  p.L104R  CYP11B2-guided Sanger seq; 
CYP11B2-guided amplicon NGS 
4 
 c.995T>G p.V332G CYP11B2-guided Sanger seq 1 
ATP2B3 c.1272_1277del p.L425_V426del CYP11B2-guided Sanger seq 1 
 c.1274_1279del p.V426_V427del CYP11B2-guided amplicon NGS 1 
CACNA1D c.1207G>C p.G403R CYP11B2-guided amplicon NGS 1 
 c.2239T>G p.F747V CYP11B2-guided Sanger seq; 
CYP11B2-guided NGS 
2 
 c.815T>A p.L272H CYP11B2-guided amplicon NGS 1 
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CLCN2 c.731G>A p.C244Y Whole exome seq (FF) 1 
Mutation 
negative 
- - CYP11B2-guided amplicon NGS 6 
 
Table 2.  Coding DNA and protein sequence variants in solitary aldosterone-producing adenomas and nodules 
Sequencing was guided by CYP11B2 immunohistochemistry from formalin-fixed paraffin-embedded resected adrenals except for the 2 indicated 
samples that were sequenced using fresh frozen (FF) tissue. *Novel variant. 
FF, fresh frozen tissue; NGS, next generation sequencing; seq, sequencing 
